GSK Topical Antibiotic Altabax “Approvable” For Traumatic Lesions
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm expects a decision in second quarter on a separate impetigo claim.
You may also be interested in...
GSK’s Altabax “Not Approvable” For Traumatic Lesions
FDA has revised its “approvable” decision from December and is now saying the secondarily infected traumatic lesions indication is “not approvable.”
GSK’s Altabax “Not Approvable” For Traumatic Lesions
FDA has revised its “approvable” decision from December and is now saying the secondarily infected traumatic lesions indication is “not approvable.”
GSK’s Altabax Clears FDA As Topical Antibacterial
Ointment is approved for impetigo due to Staphylococcus aureus or Streptococcus pyogenes in patients nine months and older.